Her2-Targeted Therapies in Non–Small Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
Nonsmall cell lung cancer (NSCLC) is diagnosed in the majority of patients in advanced stage of disease. In this setting, the prognosis is very poor with median survival of 9– 12 months and palliative chemotherapy being the standard of care. However, chemotherapy in advanced disease seems to have reached a plateau with no doublet combination shown to be clinically superior to the others. Advanc...
متن کاملTargeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations.
1 The respiratory health benefits of quitting cannabis use Donald P. Tashkin 5 Animal fur and asthma: an indoor farmyard phenomenon? Julian Crane 8 Defining airflow limitation and chronic obstructive pulmonary disease: the role of outcome studies Bruce Culver 11 Cystic fibrosis in Europe: patients live longer but are we ready? Carsten Schwarz and Dominik Hartl 13 Never too old: beneficial neuro...
متن کاملNon-small-cell lung cancer: targeted therapies
Chemotherapy: is it still enough? The major progresses in understanding cancer biology and the mechanism of oncogenesis have allowed the development of several potential molecular target drugs for cancer treatment, which are components of signaling pathways or metabolic processes contributing to the acquisition of cancer phenotype. A general better tolerability, owing to a milder toxicity profi...
متن کاملTargeted therapies in lung cancer.
The quality-of-life and overall survival are improved by platinum-based chemotherapy in patients with localized or disseminated small-cell lung cancer (SCLC) [1, 2]. In nonsmall-cell lung cancer (NSCLC), platinum-based combinations with new agents (vinorelbine, gemcitabine, taxanes) improve survival in both resected and advanced NSCLC patients [3–6]. Nevertheless, a therapeutic plateau has been...
متن کاملMulti-Targeted Therapies in Non-Small Cell Lung Cancer
E-mail: [email protected] Tel (Fax): 86-22-2352 2919 ABSTRACT Current treatment modalities provide limited improvement in the natural course of lung cancer, and prognosis remains poor. Lung cancer is a malignancy with great molecular heterogeneity. The complexity of the signaling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interferi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2006
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-06-0115